The Effect of Patient Dementia on Outpatient Clinicians' Performance on Cost Outcomes Under Medicare
痴呆症患者对门诊临床医生医疗保险成本结果表现的影响
基本信息
- 批准号:10665463
- 负责人:
- 金额:$ 2.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Contact PD/PI: Johnston, Kenton James
Project Summary
The Medicare program is implementing value-based payment (VBP), in which outpatient clinicians are paid
based on the quality and cost of the care they deliver. However, there is increasing concern these VBP
programs may not accurately measure performance among clinicians who serve high-risk patient populations,
particularly those with Alzheimer’s disease and related dementias (hereafter “dementia”). Prior research finds
that dementia is independently associated with poorer patient outcomes and markedly higher costs of care.
Furthermore, patients with dementia tend to be clustered among certain types of clinicians, such as
geriatricians. However, although Medicare adjusts clinicians’ performance under VBP for the medical risk of
their patients using the Centers for Medicare and Medicaid Services’ hierarchical condition category (CMS-
HCC) risk model, it does not adjust for dementia. This could result in systematic under-estimation of
performance for clinicians that disproportionately serve patients with dementia. Therefore, there is a critical
need for research on the effect of patient dementia on measures of clinician performance under VBP, how this
impacts providers who disproportionately serve such patients, and whether measures of dementia can be
integrated into the CMS-HCC Medicare risk adjustment model. Our long-term goal is to incorporate measures
of patient dementia into the risk adjustment system that Medicare uses in implementing VBP. The objectives of
this R21 application are to: 1) validate the adequacy of claims-based measures of dementia; 2) evaluate the
performance of a claims-based costs of care model that includes dementia by adding it to the standard CMS-
HCC risk model; and 3) demonstrate the effects of our new model versus the standard CMS-HCC model on
clinicians’ relative performance on cost measures in MIPS and the program more broadly. Our rationale for this
project is that most clinicians in the U.S. will be held accountable for their performance on cost measures
under VBP, and there is a significant risk that clinicians who disproportionately serve patients with dementia
may be negatively impacted if these factors are not accounted for by risk adjustment. This research study will
pursue three specific aims. For aim #1, we will conduct a retrospective cohort study using the Medicare
Current Beneficiary Survey (MCBS) linked to prescription drug and claims data to validate the use of claims-
based measures of dementia against patient self-report and prescription drug data. For aim #2, we will use the
most recently available Medicare claims data from the CMS Virtual Research Data Center (VRDC) to identify
the portion of Medicare costs attributable to dementia that are currently unexplained by the CMS-HCC risk
model, and evaluate a model that improves prediction by adding risk points for dementia patients. For aim #3,
we will use the CMS VRDC and Physician Compare data to assess the impact of claims-based risk adjustment
for dementia on clinician performance on VBP cost outcomes, performance scores, and reimbursement,
comparing clinicians who disproportionately serve patients with dementia to the rest of Medicare clinicians.
Project Summary/Abstract Page 6
联系PD/PI:约翰斯顿、Daughon James
项目摘要
医疗保险计划正在实施基于价值的支付(VBP),其中门诊临床医生支付
基于他们提供的医疗服务的质量和成本。然而,越来越多的人担心这些越南船民
程序可能不能准确地测量为高风险患者群体服务的临床医生的表现,
特别是那些患有阿尔茨海默病和相关痴呆(下文称为“痴呆”)的人。先前的研究发现
痴呆症与患者预后较差和护理成本明显较高独立相关。
此外,痴呆症患者倾向于聚集在某些类型的临床医生中,例如
老年病学家然而,尽管医疗保险调整了临床医生在VBP下的表现,
他们的病人使用医疗保险和医疗补助服务中心的分层条件类别(CMS-
HCC)风险模型,它不适用于痴呆症。这可能导致系统性低估
为痴呆症患者提供不成比例服务的临床医生的表现。因此,存在一个关键的
需要研究患者痴呆症对VBP下临床表现指标的影响,这是如何实现的?
影响不成比例地为这些患者提供服务的提供者,以及痴呆症的措施是否可以
CMS-HCC医疗保险风险调整模型。我们的长期目标是采取措施,
将老年痴呆症患者的风险纳入医疗保险在实施VBP时使用的风险调整系统。的目标
这个R21应用程序是:1)验证基于索赔的痴呆症措施的充分性; 2)评估
通过将其添加到标准CMS中,实现基于索赔的护理成本模型(包括痴呆症)的性能-
HCC风险模型;以及3)证明我们的新模型与标准CMS-HCC模型相比,
临床医生在MIPS和更广泛的计划中的成本措施上的相对表现。我们这样做的理由
该项目是,大多数临床医生在美国将被追究责任,他们的表现对成本的措施
根据VBP,有一个重大的风险,临床医生谁不成比例地服务于痴呆症患者
如果风险调整不考虑这些因素,可能会受到负面影响。本研究将
追求三个具体目标。对于目标#1,我们将使用Medicare进行回顾性队列研究。
当前受益人调查(MCBS)与处方药和索赔数据相关联,以验证索赔的使用-
基于痴呆症患者自我报告和处方药数据的测量。对于目标#2,我们将使用
CMS虚拟研究数据中心(VRDC)提供的最新可用Medicare索赔数据,
目前无法用CMS-HCC风险解释的可归因于痴呆症的医疗保险费用部分
模型,并评估通过增加痴呆患者的风险点来改善预测的模型。对于目标#3,
我们将使用CMS VRDC和医师比较数据来评估基于索赔的风险调整的影响
对于痴呆症,临床医生在VBP成本结果、绩效评分和报销方面的表现,
将不成比例地为痴呆症患者服务的临床医生与其他医疗保险临床医生进行比较。
项目摘要/摘要第6页
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenton James Johnston其他文献
Kenton James Johnston的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenton James Johnston', 18)}}的其他基金
Can the Medicare Quality Payment Program Incentivize Evidence-Based Treatment of Depression and Anxiety Disorders by Primary Care Providers?
医疗保险质量支付计划能否激励初级保健提供者对抑郁症和焦虑症进行循证治疗?
- 批准号:
10631718 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Can the Medicare Quality Payment Program Incentivize Evidence-Based Treatment of Depression and Anxiety Disorders by Primary Care Providers?
医疗保险质量支付计划能否激励初级保健提供者对抑郁症和焦虑症进行循证治疗?
- 批准号:
10696111 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Can the Medicare Quality Payment Program Incentivize Evidence-Based Treatment of Depression and Anxiety Disorders by Primary Care Providers?
医疗保险质量支付计划能否激励初级保健提供者对抑郁症和焦虑症进行循证治疗?
- 批准号:
10366446 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
The Effect of Patient Dementia on Outpatient Clinicians' Performance on Cost Outcomes Under Medicare Value-Based Payment.
患者痴呆症对门诊临床医生在医疗保险基于价值的支付下的成本结果的影响。
- 批准号:
10260549 - 财政年份:2020
- 资助金额:
$ 2.77万 - 项目类别:
The Effect of Patient Dementia on Outpatient Clinicians' Performance on Cost Outcomes Under Medicare Value-Based Payment.
患者痴呆症对门诊临床医生在医疗保险基于价值的支付下的成本结果的影响。
- 批准号:
10054768 - 财政年份:2020
- 资助金额:
$ 2.77万 - 项目类别:
相似海外基金
Brain Gain: Identifying candidate dementia-related biomarkers and early intervention strategies for adults aged 50+ with a history of mild traumatic brain injury - A patient-oriented research study
脑增益:为有轻度创伤性脑损伤史的 50 岁成年人识别候选痴呆相关生物标志物和早期干预策略 - 一项以患者为导向的研究
- 批准号:
495566 - 财政年份:2023
- 资助金额:
$ 2.77万 - 项目类别:
Miscellaneous Programs
QUANTIMA: Non-invasive imaging driven patient identification, stratification and outcome prognosis in dementia
QUANTIMA:非侵入性成像驱动的痴呆症患者识别、分层和结果预后
- 批准号:
10015197 - 财政年份:2022
- 资助金额:
$ 2.77万 - 项目类别:
Collaborative R&D
Medication use in community-dwelling older adults with dementia in Ontario: Applying machine learning techniques to better describe potentially inappropriate prescribing and psychotropic polypharmacy, while integrating patient and care partner perspective
安大略省社区居住的痴呆症老年人的药物使用:应用机器学习技术更好地描述潜在的不当处方和精神药物复方用药,同时整合患者和护理伙伴的观点
- 批准号:
460393 - 财政年份:2022
- 资助金额:
$ 2.77万 - 项目类别:
A communication-based intervention for early stage dementia patient-caregiver dyads to increase engagement in advance care planning and reduce caregiver burden
针对早期痴呆症患者-护理人员二人组的基于沟通的干预措施,以提高预先护理计划的参与度并减轻护理人员的负担
- 批准号:
10461153 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Sharing the diagnosis of dementia in the post-Covid clinic: patient and practitioner perspectives
分享新冠疫情后诊所中痴呆症的诊断:患者和医生的观点
- 批准号:
ES/W001349/1 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Research Grant
When dementia caregiving ends: The role of patient-caregiver social connection in caregivers' health and well-being
当痴呆症护理结束时:患者与护理人员的社会联系对护理人员的健康和福祉的作用
- 批准号:
10398011 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
C9orf72 额颞叶痴呆 (FTD) 和肌萎缩侧索硬化症 (ALS):利用患者细胞和 CRISPR 揭示治疗方法
- 批准号:
10590420 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
A communication-based intervention for early stage dementia patient-caregiver dyads to increase engagement in advance care planning and reduce caregiver burden
针对早期痴呆症患者-护理人员二人组的基于沟通的干预措施,以提高预先护理计划的参与度并减轻护理人员的负担
- 批准号:
10302023 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
C9orf72 额颞叶痴呆 (FTD) 和肌萎缩侧索硬化症 (ALS):利用患者细胞和 CRISPR 揭示治疗方法
- 批准号:
10186371 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Patient-centred volunteer program for people with dementia: a stepped wedge cluster randomised controlled trial of the MyCare Ageing program
以患者为中心的痴呆症患者志愿者计划:MyCare Aging 计划的阶梯式楔形集群随机对照试验
- 批准号:
nhmrc : 1195357 - 财政年份:2021
- 资助金额:
$ 2.77万 - 项目类别:
Investigator Grants